3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
News 2026-09-29 05:12 UTC
SHANGHAI, Sept. 29, 2026 // -- Hengrui Pharma (600276.SH; 01276.HK) today announced that it has entered into a license agreement with Novo Nordisk (Novo) for HRS-1596, a phase I-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist…
News 2026-09-29 04:44 UTC
Novo Nordisk A/S OMXCOP:NOVO_B
News 2026-09-29 04:38 UTC
Bagsværd, Denmark, 29 September 2026 — Novo Nordisk today announced that it has entered into a license agreement with Hengrui Pharma (600276.SH; 01276.HK) for HRS-1596, a phase 1-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist, with po…